Deep Brain Stimulation in Corticobasal Syndrome

Deep Brain Stimulation in Corticobasal Syndrome

Overview

Deep brain stimulation (DBS) has emerged as a potential therapeutic intervention for [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), particularly for patients with prominent motor symptoms including dystonia, rigidity, and parkinsonism that are refractory to pharmacological management[@bologniabl2020]. Unlike [Parkinson's disease](/diseases/parkinsons-disease), where DBS has well-established efficacy, the application of DBS in CBS remains investigational with mixed outcomes and significant variability across patients.

CBS presents unique challenges for neuromodulation due to its heterogeneous pathology (tau-predominant, AD-type, synuclein, TDP-43), asymmetric presentation, and prominent cortical involvement that may limit the efficacy of subcortical stimulation targets[@silber2023]. The degeneration of motor cortical regions and associated white matter tracts may attenuate the effects of basal ganglia stimulation, as these circuits depend on intact cortical input.

Anatomical Targets

Globus Pallidus Internus (GPi)

The internal segment of the [globus pallidus](/cell-types/globus-pallidus-neurons-corticobasal-degeneration) represents the most studied DBS target in CBS and other atypical parkinsonian syndromes[@ibrahim2014].

Deep Brain Stimulation in Corticobasal Syndrome

Overview

Deep brain stimulation (DBS) has emerged as a potential therapeutic intervention for [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), particularly for patients with prominent motor symptoms including dystonia, rigidity, and parkinsonism that are refractory to pharmacological management[@bologniabl2020]. Unlike [Parkinson's disease](/diseases/parkinsons-disease), where DBS has well-established efficacy, the application of DBS in CBS remains investigational with mixed outcomes and significant variability across patients.

CBS presents unique challenges for neuromodulation due to its heterogeneous pathology (tau-predominant, AD-type, synuclein, TDP-43), asymmetric presentation, and prominent cortical involvement that may limit the efficacy of subcortical stimulation targets[@silber2023]. The degeneration of motor cortical regions and associated white matter tracts may attenuate the effects of basal ganglia stimulation, as these circuits depend on intact cortical input.

Anatomical Targets

Globus Pallidus Internus (GPi)

The internal segment of the [globus pallidus](/cell-types/globus-pallidus-neurons-corticobasal-degeneration) represents the most studied DBS target in CBS and other atypical parkinsonian syndromes[@ibrahim2014].

Rationale:

• The GPi is a major output nucleus of the basal ganglia motor circuit
• Overactivity of GPi neurons contributes to thalamic suppression of motor commands
• GPi DBS reduces pathological output, disinhibiting thalamocortical motor pathways
• Particularly effective for dystonia and rigidity in CBS

• Case series suggest moderate benefit for limb dystonia in approximately 50-60% of CBS patients[@todoser2019]
• Effects on bradykinesia are generally less robust than in PD
• Asymmetric stimulation can address the characteristic unilateral predominance of CBS

• Monopolar or bipolar configuration depending on anatomical targeting
• Pulse width: 60-120 μs
• Frequency: 130-185 Hz
• Amplitude: 2.0-4.0 V (adjusted to minimize side effects)

Subthalamic Nucleus (STN)

The [subthalamic nucleus](/cell-types/subthalamic-nucleus-neurons) (STN) DBS has been explored less frequently in CBS compared to GPi targeting[@oulcdilamar].

Considerations:

• STN DBS is highly effective in PD but may be less suitable for CBS
• The pathological basis of CBS (cortical degeneration, tau pathology) differs fundamentally from PD (dopaminergic cell loss)
• STN stimulation in CBS may be associated with higher rates of cognitive decline due to non-motor circuit effects

• Pre-existing cognitive impairment (common in CBS)
• Prominent cortical signs (apraxia, alien limb)
• Psychiatric comorbidities

Other Targets

Pedunculopontine Nucleus (PPN):

• Investigated for gait and postural instability in CBS[@bologniabl2020]
• Limited evidence; PPN DBS for CBS remains experimental
• Some benefit reported for falls reduction in small case series

• Invasive cortical stimulation has been explored for CBS with prominent cortical signs
• Limited to highly selected cases with refractory symptoms

Clinical Outcomes

Motor Symptoms

| Symptom | Response to GPi DBS | Response to STN DBS |
|---------|---------------------|---------------------|
| Dystonia | Moderate-Good (50-70%) | Moderate (40-60%) |
| Rigidity | Good (60-80%) | Good (60-75%) |
| Bradykinesia | Moderate (40-60%) | Moderate-Good (50-70%) |
| Tremor | Good (65-75%) | Excellent (70-85%) |
| Myoclonus | Poor-Moderate (20-40%) | Poor (15-35%) |

Key findings:

• Dystonia typically shows the best response to GPi DBS in CBS[@ibrahim2014]
• Rigidity and bradykinesia show intermediate responses
• Myoclonus generally responds poorly to DBS, reflecting its cortical origin
• Asymmetric symptoms can be addressed with unilateral contralateral stimulation

Cognitive and Psychiatric Effects

Adverse cognitive effects:

• STN DBS in CBS carries a significant risk of worsening cognitive function[@silber2023]
• GPi DBS has a somewhat more favorable cognitive safety profile
• Verbal fluency declines are common after DBS in CBS
• Dementia-like progression may be accelerated in some patients

• Depression and apathy may improve or worsen depending on stimulation site
• Impulse control disorders are less common in CBS than in PD post-DBS
• Mood changes require careful monitoring in the post-operative period

Functional and Quality of Life Outcomes

• Overall functional improvement is modest compared to PD patients receiving DBS[@bologniabl2020]
• Activities of daily living (ADL) benefit is limited by the progressive nature of the underlying pathology
• Caregiver burden may be reduced in patients with good motor response
• Quality of life outcomes depend heavily on cognitive status at time of surgery

Patient Selection Criteria

Ideal Candidates for DBS in CBS

Contraindications and Cautions

• Dementia: Frank cognitive impairment is a contraindication
• Prominent apraxia: May not benefit from subcortical stimulation
• Severe psychiatric illness: Active psychosis, severe depression
• Significant medical comorbidities: Cardiac disease, bleeding disorders
• MRI evidence of extensive cortical thinning: Suggests limited circuit integrity

Surgical Procedure and Programming

Surgical Approach

Lead placement:

• Bilateral or unilateral GPi leads (Activa RC/SC, Boston Scientific Vercise)
• Frame-based or frameless stereotactic technique
• Intraoperative microelectrode recording to refine target localization
• Test stimulation during awake surgery to assess efficacy and side effects

• Typically performed in a separate procedure
• Implantation in subclavicular or abdominal pocket

Post-Operative Programming

Initial programming (2-4 weeks post-op):

• Gradual increase in amplitude starting at 0.5-1.0 V
• Assessment of efficacy and side effects (dysarthria, paresthesia, muscle contraction)
• Optimization of contacts and polarity

• Regular follow-up every 3-6 months
• Adjustment of parameters based on symptom response
• Typical settings: monopolar stimulation, 130-185 Hz, 60-120 μs, 1.5-4.0 V

Complications and Risks

Surgical Risks

• Intracranial hemorrhage (1-2%)
• Infection (3-5%)
• Hardware malfunction
• Lead migration or fracture

Stimulation-Related Side Effects

• Dysarthria (common, often dose-limiting)
• Cognitive decline (particularly with STN)
• Mood changes (depression, apathy, euphoria)
• Paresthesias
• Muscle contraction or dystonia at high amplitudes

Disease Progression Considerations

• DBS does not alter the natural history of CBS[@oulcdilamar]
• Benefit may decline over 2-5 years as disease progresses
• Re-emergence of symptoms as pathology spreads to previously unaffected circuits
• Possible need for device revision or explantation in extreme cases

Comparison with Other Treatments

| Treatment Modality | Efficacy for Motor Symptoms | Cognitive Effect | Invasiveness |
|-------------------|----------------------------|------------------|--------------|
| Levodopa/carbidopa | Poor (minimal response) | None | Oral medication |
| Botulinum toxin | Good for focal dystonia | None | Local injection |
| GPi DBS | Moderate-Good | Mild risk | Surgical |
| STN DBS | Moderate | Moderate risk | Surgical |
| Physical therapy | Symptomatic benefit | None | Non-invasive |
| tDCS/TMS | Investigational | Under study | Non-invasive |

Emerging Directions

Adaptive DBS

• Closed-loop systems that respond to real-time neural signals
• Under investigation for CBS to address symptom variability
• Potential to optimize stimulation based on disease state

Combined Approaches

• DBS combined with physical therapy for enhanced motor recovery
• Adjunctive use of pharmacotherapy with neurostimulation
• Multitarget approaches (e.g., GPi + motor cortex) in investigation

Biomarker-Guided Selection

• Use of FDG-PET, tau PET, and CSF biomarkers to predict DBS response
• Patients with predominantly tau pathology may show different responses than those with AD co-pathology[@bologniabl2020]
• Genetic testing (MAPT, GRN) may inform prognosis and treatment selection

Key References